Last updated: March 9, 2026
What is the drug associated with NDC 71930-0048?
NDC 71930-0048 corresponds to Vascepa (icosapent ethyl), a prescription medicine used to lower triglyceride levels in adults with hypertriglyceridemia. Vascepa is a purified ethyl ester of eicosapentaenoic acid (EPA) and is produced by Amarin Corporation.
What is the current market size for Vascepa?
Market Overview (2022-2023)
- The global market for omega-3 fatty acid drugs was valued at approximately $2.4 billion in 2022.
- Vascepa accounts for roughly 30-35% of that market.
- The U.S. segment dominates, with an estimated $800 million in revenue in 2022.
Target Patient Population
- Approximate 6 million adults in the U.S. have triglyceride levels > 200 mg/dL.
- About 10-15% of these patients qualify for Vascepa based on clinical criteria.
Competitive Landscape
- Main competitors include Epanova (Anvisa/Generics), Lipidil (Janssen), and over-the-counter Omega-3 supplements.
- Vascepa's patent exclusivity expired in 2023, opening potential for generics.
How does the patent and regulatory status impact the market?
- Amarin's patent protection on Vascepa’s formulation extended to 2023.
- A generic version was approved by the FDA in late 2022, with market entry expected by Q2 2023.
- Patent litigation and settlement agreements could delay generic commercialization.
What are the price trends and projections?
Current Pricing
| Pricing Metric |
2022 Data |
| Average wholesale price (AWP) per 30-count capsule |
$4.50 - $6.50 |
| Commercial insurance average copay |
$20-$35 |
| Estimated retail price for a 30-day supply |
$135 - $195 |
Historical Trends
- Vascepa's retail price per month has remained relatively steady since launch.
- Price discounts and rebates are common with commercial payers, reducing consumer out-of-pocket costs.
Post-Patent Market Dynamics
- Introduction of generics likely to reduce retail prices by 30–50%.
- Industry estimates suggest a baseline wholesale price for generic EPA products around $2-$3 per capsule.
Price Forecast (Next 3 Years)
| Year |
Wholesale Price per Capsule |
Retail Price per Month |
Key Factors |
| 2023 |
$4.00 - $6.00 |
$120 - $180 |
Patent expiry; early generic competition |
| 2024 |
$2.00 - $3.00 |
$60 - $90 |
Market saturation with generics; cost reductions |
| 2025 |
$1.50 - $2.50 |
$45 - $75 |
Increased generic market share, formulary adjustments |
What impact do regulatory and market factors have on pricing?
- FDA approval of generics accelerates downward price pressure.
- Formulary decisions favor cost-effective generics, reducing reimbursement rates for branded Vascepa.
- Insurance coverage remains variable; some payers negotiate substantial rebates, affecting net prices.
What is the outlook for revenue generation?
- Branded Vascepa likely to experience revenue decline 15-25% annually post-generic entry, assuming no new indications.
- New indications or formulations could stabilize revenues.
- Market share may shift toward generics, but premium positioning for branded Vascepa may preserve a niche.
Key Considerations for Stakeholders
- Manufacturers should strategize pricing and patent litigation.
- Investors need to monitor regulatory approvals and market entry of generics.
- Healthcare providers and payers will prioritize cost-effectiveness, influencing formulary decisions.
Key Takeaways
- The primary driver for Vascepa’s market value is its clinical efficacy in hypertriglyceridemia and related cardiovascular outcomes.
- Patent expiration in 2023 will lead to significant price declines due to generic competition.
- Wholesale prices are projected to drop by approximately 50% within two years of generic market entry.
- The overall market for omega-3 therapies remains robust but will increasingly shift toward generics.
FAQs
Q1: How soon will generics fully penetrate the Vascepa market?
A1: Expect generics to capture a significant share within 12-24 months after FDA approval, potentially reaching 60-70% market share by 2024.
Q2: Will branded Vascepa maintain premium pricing?
A2: Likely, if it secures additional indications or demonstrates superior efficacy for specific patient populations.
Q3: How do insurance formularies impact retail prices?
A3: Payers negotiate rebates and preferential placement, often reducing consumer copays and retail prices.
Q4: Are there regulatory risks affecting Vascepa's market?
A4: Yes; legal challenges related to patent rights and subsequent approval of generics influence pricing and supply.
Q5: What opportunities exist for new formulations or delivery methods?
A5: Innovations such as extended-release formulations or combination therapies could open new markets, potentially preserving higher prices.
Sources:
[1] Amarin Corporation. (2022). Vascepa data sheet.
[2] IQVIA. (2022). U.S. Prescription Drug Market Reports.
[3] FDA. (2022). Approval documentation for Vascepa and generic EPA products.
[4] MarketWatch. (2023). Omega-3 Market Outlook.
